Liver Cancer

November 26th 2024

Patients with locally advanced hepatocellular carcinoma (HCC) who achieve a complete response after locoregional therapy and immunotherapy may be able to follow a watch-and-wait protocol.

November 24th 2024

Patients experienced similar safety and efficacy if they received first-line or later-line treatment for unresectable hepatocellular carcinoma (u-HCC).

November 21st 2024

The FDA approved a phase 3 trial to assess amezalpat with the current standard of care in unresectable or metastatic hepatocellular carcinoma.

November 14th 2024

A new risk score model for hepatocellular carcinoma using standard clinical data can better identify individuals at risk better than the current standard risk models.